<DOC>
	<DOCNO>NCT01218061</DOCNO>
	<brief_summary>The main objective study follow prospectively cohort patient pre-diabetes understand pathophysiological mechanism involve switch pre-diabetes type 2 diabetes identify new biomarkers type 2 diabetes risk population .</brief_summary>
	<brief_title>Therapeutic Innovation Type 2 DIABetes ( IT-DIAB )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Adult patient ( ≥18 year ) Subjects diabetes risk score ≥ 15 Subjects impaired fast glucose : blood glucose ≥ 1.10 g/l &lt; 1 .26 g/L Subjects affiliate appropriate social security system Fasting glycemia ≥ 1.26 g/l Fasting glycemia ≤ 1.10 g/l Subjects previously treat oral antidiabetic : metformin , glitazones , inhibitor αglucosidase , sulfonylurea , repaglinide , inhibitor DPPIV , GLP1 R agonist . Subjects previously treat insulin , except gestational diabetes Severe coagulation disorder Thrombocytopenia &lt; 100 000/mm 3 Severe psychiatric disorder Severe renal insufficiency ( creatinine clearance &lt; 30 ml/min ) Severe hepatic insufficiency ( TP &lt; 50 % ) Alcohol abuse ( &gt; 30g/j ) Patient 's opposition Subject unable follow study 5 year followup Subject exclusion period previous study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pre-diabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Cohort</keyword>
	<keyword>Diabetes Risk Score</keyword>
</DOC>